Catalog: | C1324T |
Product Type: | Test kit |
Unit: | 96 tests |
Assay time: | 2.5 hours |
Limit of detection: | 0.026 amol/μl |
Sample type: | Cardiovascular disease, Oncology, Neurodegenerative disease |
Analysis mode: | miREIA – miRNA enzyme immunoassay |
Storage: | 2–8°C |
Application: | Cardiovascular disease, Oncology, Neurodegenerative disease |
MiR-26b is located in an intron of the Ctdsp2 gene and it can regulate neuronal differentiation together with its host gene. MiR-26b has been reported to be a critical regulator in carcinogenesis and tumor progression by acting as a tumor suppressor gene in various types of cancer. It has been found that miR-26b is downregulated in breast cancer and that it can inhibit cellular proliferation. Down-regulation of miR-26b in osteosarcoma increased the levels of CTGF and Smad1, facilitating osteosarcoma metastasis. MiR-26b could also modulate non-small cell lung cancer chemoresistance and migration through its association with PTEN. In addition, a recent study demonstrated that miR-26b-5p suppresses proliferation, migration and invasion of intrahepatic cholangiocarcinoma cells by suppressing S100A7. Similarly, downregulation of miR-26b-5p together with miR-26a-5p was frequently observed in bladder cancer cells, and both of these miRNAs significantly inhibited cancer cell migration and invasion. Besides cancer, aberrant expression and functional abnormalities of miR-26b have been reported in a variety of other diseases. The results suggest that miR-26b plays a role in maintenance of heart function by regulating Wnt pathway. miR-26 has been observed to be upregulated in the human temporal cortex in Alzheimer's disease and in APP/PS1 double-transgenic mice, suggesting that miR-26b may function in development of Alzheimer's disease.
Copyright © 2024 Creative Biogene. All rights reserved.